The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 2, 2005, Pages 272-279

  He, S ^a   Jacobsson Ekman, G ^a   Hedner, Ulla ^b,c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c NOVO NORDISK A S   (Denmark)

^d NONE   (Sweden)

Author keywords

Activated FVII; Fibrin permeability; FVII; Overall fibrinolysis potential (OFP); Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; FIBRIN; LIPOCORTIN 5; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLOOD CLOT; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; FREEZE THAWING; GEL; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; THROMBOCYTE; ADULT; BLOOD; CHEMISTRY; CONFOCAL MICROSCOPY; CRYOPRESERVATION; DRUG EFFECT; FEMALE; MIDDLE AGED; PERMEABILITY; PHYSIOLOGY;

ADULT; ANNEXIN A5; BLOOD PLATELETS; CRYOPRESERVATION; FACTOR VII; FEMALE; FIBRIN; GELS; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICROSCOPY, CONFOCAL; MIDDLE AGED; PERMEABILITY; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 20844443318     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01127.x     Document Type: Article

References (28)

1. Carr M, Shen L, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
2. Blomback B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
3. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel achitectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
4. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-19.
5. Wolberg AS, Monroe DM, Hedner U, Roberts HR. High dose factor VIIa enhances clot stability in a model of hemophilia. Blood 2001; 98: 826a (Abstract 3435).
6. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transf Sci 1998; 19: 163-76.
7. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilial patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
8. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model. Br J Haematol 2001; 114: 114-20.
9. He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 1: 355-61.
10. Blomback M, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
11. Sixma JJ, Wester J. The hemostatic plug. Semin Hematol 1977; 14: 265-99.
12. Corrigan JJ Jr. Oral bleeding in hemophilia: treatment with epsilon-aminocaproic acid in the management of dental extractions in the hemophiliacs. Am J Med Sci 1964; 248: 184.
13. Forbes CD, Barr RD, Reid G, Thomson G, Prentice CR, McNicol GP, Douglas AS. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. BMJ 1972; 2: 311-13.
14. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61.
15. Collet JP, Montalescot G, Lesty C, Mishal Z, Soria J, Choussat R, Drobinski G, Soria C, Pinton P, Barragan P, Thomas D. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-34.
16. Aberg M, Bergentz S-E, Hedner U. Effect of dextran and induced thrombocytopenia on the lysability of ex vivo thrombi in dogs. Acta Chir Scand 1977; 143: 91-4.
17. Aberg M, Rausing A. The effect of dextran 70 on the structure of ex vivo thrombi. Thromb Res 1978; 12: 1113-22.
18. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hemat Oncol 2003; 1: 112-9.
19. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
20. Kjalke M, Johannesson M, Hedner U. Effect of recombinant factor Vila (NovoSeven) on thrombocytopenia-like conditions in vitro. Semin Hematol 2001; 38: 15-20.
21. Alkjaersig N, Abe T, Seegers WH. Purification and quantitative determination of platelet factor 3. Am J Physiol 1955; 181: 304.
22. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 1991; 5: 146-54.
23. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
24. Vanschoonbeek K, Feijge MAH, van Kampen RJW, Kenis H, Hemker HC, Giesen PLA, Heemskerk JWM. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476-84.
25. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
26. Poon MC, d'Oiron R, Hann I, Negrier C, de Lumley L, Thomas A, Karafoulidou A, Deniers C, Street A, Hulth-Kuhne A, Petrini P, Fressinaud E, Morfini M, Tengborn L, Marques-Verdier A, Musso R, Devecioglu O, Houston DS, Lethagen S, Van Geet C, von Depka M, Berger C, Beurrier P, Britton HA, Gerrits W, Guthner C, Kuhle S, Lorenzo JJ, Makris PE, Nohe N, Paugy P, Pautard B, Torchet MF, Trillot N, Vicariot M, Wilde J, Winter M, Chambost H, Ingerslev J, Peters M, Strauss G. Use of recombinant factor Vila (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38: S21-5.
27. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor Vila. Clin Pharmacol Ther 1994; 55: 638-48.
28. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 450-5.